The global Liquid Biopsy For Cancer Diagnostics market size is predicted to grow from US$ 4728 million in 2025 to US$ 9773 million in 2031; it is expected to grow at a CAGR of 12.9% from 2025 to 2031.

Liquid biopsy for cancer diagnostics refers to a non-invasive medical test that analyzes blood or other body fluids to detect and analyze genetic alterations, proteins, or other molecules associated with cancer. Unlike traditional biopsies, which involve the surgical removal of a tissue sample, liquid biopsies provide a less invasive and more accessible method for detecting and monitoring cancer.

Researchers and developers continue to explore and expand the clinical utility of liquid biopsy. This includes investigating its application in various cancer types, different stages of cancer, and for monitoring treatment response and minimal residual disease.

ReportPrime' newest research report, the “Liquid Biopsy For Cancer Diagnostics Industry Forecast” looks at past sales and reviews total world Liquid Biopsy For Cancer Diagnostics sales in 2024, providing a comprehensive analysis by region and market sector of projected Liquid Biopsy For Cancer Diagnostics sales for 2025 through 2031. With Liquid Biopsy For Cancer Diagnostics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Liquid Biopsy For Cancer Diagnostics industry.

This Insight Report provides a comprehensive analysis of the global Liquid Biopsy For Cancer Diagnostics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Liquid Biopsy For Cancer Diagnostics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Liquid Biopsy For Cancer Diagnostics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Liquid Biopsy For Cancer Diagnostics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Liquid Biopsy For Cancer Diagnostics.

This report presents a comprehensive overview, market shares, and growth opportunities of Liquid Biopsy For Cancer Diagnostics market by product type, application, key players and key regions and countries.

Segmentation by Type:

• Blood Test
• Urine Test
• Saliva Test

Segmentation by Application:

• Hospital
• Diagnostic Center
• Others

Market by Region:

• Americas
• APAC
• Europe
• Middle East & Africa

Company's Coverage:

• F. Hoffman La Roche Ltd.
• Thermo Fisher Scientific Inc.
• Agilent Technologies Inc.
• Illumina Inc.
• The Menarini Group
• Bio-Rad Laboratories Inc.
• QIAGEN Inc.
• Exact Sciences Corporation
• Bio-Techne Corporation
• ArcherDX Inc.
• Neogenomics Laboratories Inc.
• Guardant Health Inc.
• Myriad Genetics Inc.
• Foundation Medicine Inc.
• Amoy Diagnostics Co. Ltd.
• Biocartis Group NV

Key Questions Addressed in this Report: